Leap Therapeutics Shares Jump on $59M Winklevoss-Led Crypto Deal

Core Viewpoint - Leap Therapeutics (LPTX) shares surged by 25% following the announcement of a $58.9 million private investment led by Winklevoss Capital to initiate a crypto treasury strategy [1][3]. Group 1: Investment Details - The investment is structured as a private placement, including common shares and warrants priced at $0.61439 per unit [1]. - Winklevoss Capital, founded by Cameron and Tyler Winklevoss, will acquire two board seats at Leap as part of the investment [1]. Group 2: Use of Funds - Leap plans to allocate a portion of the capital to purchase cryptocurrency as part of a long-term strategy to hold crypto on its balance sheet [2]. - The remaining funds will be directed towards the clinical development of its drug candidates [2]. Group 3: Market Position - This deal positions Leap among a growing number of public companies utilizing cryptocurrency as a treasury reserve [2]. - Further details regarding Leap's digital asset strategy are expected to be announced soon, although specific assets for acquisition have not been disclosed [2].